Mylan confident on biosim Herceptin in India despite Roche tactics
This article was originally published in Scrip
Executive Summary
Mylan has said that it and partner Biocon were given no prior warning of the recent legal action by Roche when the Swiss company sought to block their biosimilar versions of Herceptin (trastuzumab) in India.
You may also be interested in...
Biocon-CHAI Cancer Biosimilars Deal Promises Large Savings
Biocon Biologics strikes deal with the Clinton Health Access Initiative to provide cost-effective alternatives to pricey reference biologics, beginning with trastuzumab and pegfilgrastim. Savings of over 59% for buyers are expected in some cases.
Court: No Herceptin Biosimilar Tag For Indian Trastuzumabs
An Indian court appears to have delivered a frontal blow to defendants Biocon and Mylan in a hotly contested case concerning their biosimilar versions of Roche's Herceptin (trastuzumab).
Court: No Herceptin Biosimilar Tag For Indian Trastuzumabs
An Indian court appears to have delivered a frontal blow to defendants Biocon and Mylan in a hotly contested case concerning their biosimilar versions of Roche's Herceptin (trastuzumab).